AIMS/HYPOTHESIS: The secretory function of pancreatic beta cells is synergistically stimulated by two signalling pathways which mediate the effects of nutrients and hormones such as glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) or glucagon. These hormones are known to activate adenylyl cyclase in beta cells. We examined the type of adenylyl cyclase that is associated with this synergistic interaction. METHODS: Insulin release, cAMP production, adenylyl cyclase activity, mRNA and protein expression were measured in fluorescence-activated cell sorter-purified rat beta cells and in the rat beta-cell lines RINm5F, INS-1 832/13 and INS-1 832/2. RESULTS: In primary beta cells, glucagon and GLP-1 synergistically potentiate the stimulatory effect of 20 mmol/l glucose on insulin release and cAMP production. Both effects are abrogated in the presence of the L-type Ca(2+)-channel blocker verapamil. The cAMP-producing activity of adenylyl cyclase in membranes from RINm5F cells is synergistically increased by Ca(2+)-calmodulin and recombinant GTP(gamma)S-activated G(s alpha)-protein subunits. This type of regulation is characteristic for type I and type VIII AC isoforms. Consistent with this functional data, AC mRNA analysis shows abundant expression of type VI AC, four splice variants of type VIII AC and low expression level of type I AC in beta cells. Type VIII AC expression at the protein level was observed using immunoblots of RINm5F cell extracts. CONCLUSION/ INTERPRETATION: This study identifies type VIII AC in insulin-secreting cells as one of the potential molecular targets for synergism between GLP-1 receptor mediated and glucose-mediated signalling.
AIMS/HYPOTHESIS: The secretory function of pancreatic beta cells is synergistically stimulated by two signalling pathways which mediate the effects of nutrients and hormones such as glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) or glucagon. These hormones are known to activate adenylyl cyclase in beta cells. We examined the type of adenylyl cyclase that is associated with this synergistic interaction. METHODS: Insulin release, cAMP production, adenylyl cyclase activity, mRNA and protein expression were measured in fluorescence-activated cell sorter-purified rat beta cells and in the rat beta-cell lines RINm5F, INS-1 832/13 and INS-1 832/2. RESULTS: In primary beta cells, glucagon and GLP-1 synergistically potentiate the stimulatory effect of 20 mmol/l glucose on insulin release and cAMP production. Both effects are abrogated in the presence of the L-type Ca(2+)-channel blocker verapamil. The cAMP-producing activity of adenylyl cyclase in membranes from RINm5F cells is synergistically increased by Ca(2+)-calmodulin and recombinant GTP(gamma)S-activated G(s alpha)-protein subunits. This type of regulation is characteristic for type I and type VIII AC isoforms. Consistent with this functional data, AC mRNA analysis shows abundant expression of type VI AC, four splice variants of type VIII AC and low expression level of type I AC in beta cells. Type VIII AC expression at the protein level was observed using immunoblots of RINm5F cell extracts. CONCLUSION/ INTERPRETATION: This study identifies type VIII AC in insulin-secreting cells as one of the potential molecular targets for synergism between GLP-1 receptor mediated and glucose-mediated signalling.
Authors: K Miyawaki; Y Yamada; H Yano; H Niwa; N Ban; Y Ihara; A Kubota; S Fujimoto; M Kajikawa; A Kuroe; K Tsuda; H Hashimoto; T Yamashita; T Jomori; F Tashiro; J Miyazaki; Y Seino Journal: Proc Natl Acad Sci U S A Date: 1999-12-21 Impact factor: 11.205
Authors: C Ammälä; L Eliasson; K Bokvist; P O Berggren; R E Honkanen; A Sjöholm; P Rorsman Journal: Proc Natl Acad Sci U S A Date: 1994-05-10 Impact factor: 11.205
Authors: K Moens; H Heimberg; D Flamez; P Huypens; E Quartier; Z Ling; D Pipeleers; S Gremlich; B Thorens; F Schuit Journal: Diabetes Date: 1996-02 Impact factor: 9.461
Authors: Luis R Landa; Mark Harbeck; Kelly Kaihara; Oleg Chepurny; Kajorn Kitiphongspattana; Oliver Graf; Viacheslav O Nikolaev; Martin J Lohse; George G Holz; Michael W Roe Journal: J Biol Chem Date: 2005-06-29 Impact factor: 5.157
Authors: B Roger; J Papin; P Vacher; M Raoux; A Mulot; M Dubois; J Kerr-Conte; B H Voy; F Pattou; G Charpentier; J-C Jonas; N Moustaïd-Moussa; J Lang Journal: Diabetologia Date: 2010-11-03 Impact factor: 10.122
Authors: Debbie Willoughby; Michelle L Halls; Katy L Everett; Antonio Ciruela; Philipp Skroblin; Enno Klussmann; Dermot M F Cooper Journal: J Cell Sci Date: 2012-09-12 Impact factor: 5.285
Authors: Agnes C L Martin; Debbie Willoughby; Antonio Ciruela; Laura-Jo Ayling; Mario Pagano; Sebastian Wachten; Anders Tengholm; Dermot M F Cooper Journal: Mol Pharmacol Date: 2009-01-26 Impact factor: 4.436
Authors: Sarah Melissa P Jacobo; Marcy L Guerra; Rachel E Jarrard; Julie A Przybyla; Guohong Liu; Val J Watts; Gregory H Hockerman Journal: J Pharmacol Exp Ther Date: 2009-04-07 Impact factor: 4.030